Last updated 16 days ago

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

858 patients around the world
Available in Puerto Rico, Brazil, United States, Argentina
Sanofi
1Research sites
858Patients around the world
This study is for people with
Multiple sclerosis
Secondary progressive multiple sclerosis
Requirements for the patient
To 60 Years
All Gender
Medical requirements
Sites
Instituto de Neurología Cognitiva (INECO)
Recruiting
Marcelo Torcuato de Alvear 1632, C1021 Cdad. Autónoma de Buenos Aires, Argentina
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy